BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders (“Holders”) of its senior secured convertible notes (the “Notes”) have agreed to amend certain terms of the Notes and other concessions,

Patients with moderate to severe plaque psoriasis showed meaningful improvements in skin, itch and quality-of-life measures among PASI 75 non-responders treated with OTEZLA, according to a post hoc sub-analysis of data from the phase 3 ESTEEM 1 trial

Investors and other interested parties are invited to listen to the conference call

Sixty-six-year-old U.S. Army veteran Gary “Lou” Dehnert will be taking a Stars & Stripes Honor Flight on September 15th 2018 to Washington, D.C. where he will visit memorials dedicated to honoring his fellow veterans’ service and sacrifices.

Research award will support preclinical activities to advance product candidate for the treatment of interstitial cystitis/bladder pain syndrome into the clinic

Technology leader from Kaiser Permanente and Oracle to lead innovative healthcare interoperability startup

Indivior PLC today announced that due to adverse weather expected from Hurricane Florence, the recently declared state of emergency in Virginia and its likely impact on East Coast travel, the Company is unable to participate in Morgan Stanley’s 16th Annual Global Healthcare Conference.

For many Canadians, life is a balancing act. Between a full-time job, family commitments and social obligations, finding time to care for your financial, physical and mental health can be tough.

VivaLNK’s Vital Scout to be used in a Stanford study to help quantify stress reactivity and recovery in order to explore links with teenage depression

Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations